We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

News

0

TASECTAN® launched in Croatia by JGL

Noventure is proud to announce the launch of TASECTAN® in Croatia by its partner company JGL, under the brand Normia Stop. TASECTAN® acts by forming a film which protects the intestinal mucosa, reducing the frequency and duration of diarrhea episodes in adults, children and infants. TASECTAN® is marketed in 40 countries with growing sales of more than two million packs per year (ex-factory, as reported by commercial partners). TASECTAN® is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments (CE 0373, Noventure SL).

Read more

GELSECTAN® launched in Finland

We are glad to announce the launch of GELSECTAN® in Finland by our partner company Sabora. GELSECTAN® belongs to a new class of products defined as “mucosal protectors”, which help restore the normal function of the epithelial barrier in the gut. It is intended to relieve and prevent IBS symptoms such as chronic or relapsing diarrhea, pain and bloating.

Read more

Let's meet in..

2019, Jun 03

euroPLX 70 Berlin

Read more

2019, Jun 05

ESPGHAN 52

Read more

2019, Jun 13

Réunion annuelle du Groupe Français de Neuro-Gastroentérologie GFNG 2019

Read more

2019, Jun 14

Gastro Update Europe 2019

Read more

2019, Sep 05

NeuroGASTRO 2019

Read more

2019, Oct 19

UEG Week 2019

Read more